Korean Celltrion Signs Letter Of Intent With CDC To Develop Rabies Agents
This article was originally published in The Pink Sheet Daily
Executive Summary
Celltrion hopes to begin manufacturing and marketing the drug by 2014 after wrapping up the development and subsequent clinical trials.